Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors

(2013) Madeleine SQ Kortenhorst et al.   Epigenetics

Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

(2013) Michel D. Wissing et al.   FASEB JOURNAL

Aurora Kinase Inhibition As an Anticancer Strategy

(2013) John F. Hilton et al.   JOURNAL OF CLINICAL ONCOLOGY

Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells

(2012) Maria Fadri-Moskwik et al.   FASEB JOURNAL

Aurora B kinase phosphorylates and instigates degradation of p53

(2012) C. P. Gully et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

(2011) L. Kretzner et al.   CANCER RESEARCH

Pharmacological inhibition of Aurora-A but not Aurora-B impairs interphase microtubule dynamics

(2011) Corinne Lorenzo et al.   CELL CYCLE

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The role of histone deacetylases in prostate cancer

(2010) Ata Abbas et al.   Epigenetics

Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells

(2010) Jung Jin Hwang et al.   JOURNAL OF UROLOGY

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers

(2010) Kakoli Das et al.   PATHOLOGY

Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor

(2010) Sushant K. Kachhap et al.   PLoS One

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)

(2009) Deborah Bradley et al.   CANCER

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors

(2008) M. S.Q. Kortenhorst et al.   CLINICAL CANCER RESEARCH

Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells

(2008) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Dissecting the role of Aurora A during spindle assembly

(2008) Teresa Sardon et al.   EMBO JOURNAL

Histone Deacetylase Inhibitors Promote Apoptosis and Senescence in Human Mesenchymal Stem Cells

(2008) Giovanni Di Bernardo et al.   STEM CELLS AND DEVELOPMENT

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts

(2007) Lalji K. Gediya et al.   BIOORGANIC & MEDICINAL CHEMISTRY